Abstract
An early phase II multicentered study of YM 881 (zinostatin stimalamer) was conducted in 36 patients to investigate response and the safety of the drug in malignant tumors. The response could be evaluated in 18 patients, one with brain tumor, 2 with lung cancer, one with breast cancer, one with liver cancer, one with pancreatic cancer, 6 with gastric cancer, and 6 with colon cancer. PR was found in the patient with brain tumor. Major subjective unwanted effects were gastrointestinal symptoms. Objective evidence of hematological changes (thrombocytopenia, decreased hematocrit, and lymphocytopenia) was also obtained.
Publication types
-
Clinical Trial
-
English Abstract
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Anorexia / chemically induced
-
Brain Neoplasms / drug therapy
-
Drug Evaluation
-
Female
-
Humans
-
Injections, Intravenous
-
Lung Neoplasms / drug therapy
-
Male
-
Maleic Anhydrides / administration & dosage
-
Maleic Anhydrides / adverse effects
-
Maleic Anhydrides / therapeutic use*
-
Middle Aged
-
Neoplasms / drug therapy*
-
Polystyrenes / administration & dosage
-
Polystyrenes / adverse effects
-
Polystyrenes / therapeutic use*
-
Stomach Neoplasms / drug therapy
-
Thrombocytopenia / chemically induced
-
Vomiting / chemically induced
-
Zinostatin / administration & dosage
-
Zinostatin / adverse effects
-
Zinostatin / analogs & derivatives*
-
Zinostatin / therapeutic use
Substances
-
Maleic Anhydrides
-
Polystyrenes
-
poly(maleic acid-styrene)neocarzinostatin
-
Zinostatin